Castle Biosciences CSTL Dermatologic — NET REVENUES

Other product segments

Similar metrics at other companies

MDIABarter — NET REVENUES

$486K+10.7%

MDIADigital — NET REVENUES

$15.54M+62.9%

MDIAOther — NET REVENUES

$1.16M-25.2%

MDIASyndication — NET REVENUES

$332K-50.3%

MDIAEvents and Sponsorships — NET REVENUES

$155K-35.1%

MDIAAudio — NET REVENUES

$9.76M-28.7%

FAQ

What is Castle Biosciences's dermatologic — NET REVENUES?

Castle Biosciences (CSTL) reported dermatologic — NET REVENUES of $41.11M in Q1 2026.

How has Castle Biosciences's dermatologic — NET REVENUES changed year-over-year?

Castle Biosciences's dermatologic — NET REVENUES decreased by 34.7% year-over-year, from $62.96M to $41.11M.

What is the long-term trend for Castle Biosciences's dermatologic — NET REVENUES?

Over 4 years (2021 to 2025), Castle Biosciences's dermatologic — NET REVENUES has grown at a 26.0% compound annual growth rate (CAGR), from $85.75M to $216.37M.

What does dermatologic — NET REVENUES mean?

This metric represents the total revenue generated from the sale of genomic diagnostic tests and related services within the company's dermatological cancer product portfolio. It reflects the market adoption and commercial performance of specialized diagnostic tools used by physicians to inform treatment decisions for skin cancers. Tracking this revenue stream provides insight into the company's core business growth and the competitive positioning of its dermatological diagnostic offerings.